Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2017

Open Access 01-12-2017 | Erratum

Erratum to: Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI

Authors: Nathaniel M. Braman, Maryam Etesami, Prateek Prasanna, Christina Dubchuk, Hannah Gilmore, Pallavi Tiwari, Donna Plecha, Anant Madabhushi

Published in: Breast Cancer Research | Issue 1/2017

Login to get access

Excerpt

This article [1] has been updated to correct the spelling of one of the author’s names. Donna Plecha’s name was incorrectly spelt as Pletcha when this article originally published. …
Literature
1.
Braman NM, Maryam E, Prateek P, Christina D, Hannah G, Pallavi T, Donna P, Anant M. Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI. Breast Cancer Res. 2017;19:57. doi:10.​1186/​s13058-017-0846-1.CrossRefPubMedPubMedCentral
Metadata
Title
Erratum to: Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI
Authors
Nathaniel M. Braman
Maryam Etesami
Prateek Prasanna
Christina Dubchuk
Hannah Gilmore
Pallavi Tiwari
Donna Plecha
Anant Madabhushi
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2017
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/s13058-017-0862-1

Other articles of this Issue 1/2017

Breast Cancer Research 1/2017 Go to the issue

Review

Decision making for breast cancer prevention among women at elevated risk

Research Article

Phosphoproteomics reveals network rewiring to a pro-adhesion state in annexin-1-deficient mammary epithelial cells

Research Article

GPER mediates the angiocrine actions induced by IGF1 through the HIF-1α/VEGF pathway in the breast tumor microenvironment

Research article

PIK3CA mutations are common in lobular carcinoma in situ, but are not a biomarker of progression

Research article

An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation

Research article

Pathomimetic avatars reveal divergent roles of microenvironment in invasive transition of ductal carcinoma in situ
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits